Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers


  Sexually Transmitted Diseases

  Free Subscription

Articles published in Int J Cancer

Retrieve available abstracts of 168 articles:
HTML format

Single Articles

    April 2020
  1. REN J, Xu W, Su J, Ren X, et al
    Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable.
    Int J Cancer. 2020;146:2166-2174.
    PubMed     Abstract available

  2. IDAHL A, Cornet CL, Maldonado SG, Waterboer T, et al
    Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
    Int J Cancer. 2020 Apr 3. doi: 10.1002/ijc.32999.
    PubMed     Abstract available

    March 2020
  3. HAMMER A, Demarco M, Campos N, Befano B, et al
    Study of the Risks of CIN3+ detection following multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
    Int J Cancer. 2020 Mar 6. doi: 10.1002/ijc.32950.
    PubMed     Abstract available

    February 2020
  4. VENETIANER R, Clarke MA, van der Marel J, Tota J, et al
    Identification of HPV Genotypes Causing Cervical Pre-Cancer using Tissue-Based Genotyping.
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32919.
    PubMed     Abstract available

  5. CLEVELAND AA, Gargano JW, Park IU, Griffin MR, et al
    Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Int J Cancer. 2020;146:810-818.
    PubMed     Abstract available

    January 2020
  6. NAKAGAWA T, Matsusaka K, Misawa K, Ota S, et al
    Stratification of HPV-associated and HPV-negative oropharyngeal squamous cell carcinomas based on DNA methylation epigenotypes.
    Int J Cancer. 2020 Jan 30. doi: 10.1002/ijc.32890.
    PubMed     Abstract available

  7. ZHAO XL, Xu XQ, Duan XZ, Rezhake R, et al
    Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in 'colposcopy and treat' approach: a population-based study in rural China.
    Int J Cancer. 2020 Jan 22. doi: 10.1002/ijc.32881.
    PubMed     Abstract available

  8. CHAN K, Liu SS, Wei N, Ngu SF, et al
    Primary HPV testing with cytology versus cytology alone in cervical screening - a prospective randomized controlled trial (RCT) with two rounds of screening in a Chinese population.
    Int J Cancer. 2020 Jan 10. doi: 10.1002/ijc.32861.
    PubMed     Abstract available

    December 2019
  9. KANN H, Hortlund M, Eklund C, Dillner J, et al
    Human Papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case-control study.
    Int J Cancer. 2019 Dec 23. doi: 10.1002/ijc.32848.
    PubMed     Abstract available

  10. ELFSTROM KM, Sundstrom K, Andersson S, Bzhalava Z, et al
    Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study.
    Int J Cancer. 2019;145:3033-3039.
    PubMed     Abstract available

    November 2019
  11. VEYER D, Wack M, Mandavit M, Garrigou S, et al
    HPV circulating tumoral DNA quantification by droplet-based digital PCR: a promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers.
    Int J Cancer. 2019 Nov 22. doi: 10.1002/ijc.32804.

  12. LEHTINEN M, Apter D, Eriksson T, Harjula K, et al
    Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females - results from a community-randomized trial.
    Int J Cancer. 2019 Nov 17. doi: 10.1002/ijc.32791.
    PubMed     Abstract available

  13. COSPER PF, McNair C, Gonzalez I, Wong N, et al
    Decreased Local Immune Response and Retained HPV Gene Expression during Chemoradiotherapy are Associated with Treatment Resistance and Death from Cervical Cancer.
    Int J Cancer. 2019 Nov 15. doi: 10.1002/ijc.32793.
    PubMed     Abstract available

  14. YANG Y, Meng YL, Duan SM, Zhan SB, et al
    REBACIN(R) as a noninvasive clinical intervention for high-risk human papillomavirus persistent infection.
    Int J Cancer. 2019;145:2712-2719.
    PubMed     Abstract available

  15. ORUMAA M, Leinonen MK, Campbell S, Moller B, et al
    Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.
    Int J Cancer. 2019;145:2629-2638.
    PubMed     Abstract available

    October 2019
  16. SAND FL, Kjaer SK, Frederiksen K, Dehlendorff C, et al
    Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status.
    Int J Cancer. 2019 Oct 24. doi: 10.1002/ijc.32752.
    PubMed     Abstract available

  17. FOKOM DOMGUE J, Futuh B, Ngalla C, Kakute P, et al
    Feasibility of a Community-based Cervical Cancer Screening with 'Test and Treat' strategy using self-sample for an HPV Test: Experience from rural Cameroon, Africa.
    Int J Cancer. 2019 Oct 21. doi: 10.1002/ijc.32746.
    PubMed     Abstract available

  18. BRAUN JA, Herrmann AL, Blase JI, Frensemeier K, et al
    Effects of the Antifungal Agent Ciclopirox in HPV-Positive Cancer Cells: Repression of Viral E6/E7 Oncogene Expression and Induction of Senescence and Apoptosis.
    Int J Cancer. 2019 Oct 11. doi: 10.1002/ijc.32709.
    PubMed     Abstract available

  19. MADATHIL S, Rousseau MC, Joseph L, Coutlee F, et al
    Latency of tobacco smoking for head and neck cancer among HPV-positive and HPV-negative individuals.
    Int J Cancer. 2019 Oct 4. doi: 10.1002/ijc.32708.
    PubMed     Abstract available

  20. ZORZI M, Del Mistro A, Giorgi Rossi P, Laurino L, et al
    Risk of CIN2 or more severe lesions after negative HPV-mRNA E6/E7 overexpression assay and after negative HPV-DNA test: concurrent cohorts with a 5-year follow up.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32695.
    PubMed     Abstract available

  21. BETTAMPADI D, Villa LL, Lazcano Ponce E, Salmeron J, et al
    Oral Human Papillomavirus Prevalence and Type Distribution by Country (Brazil, Mexico and the United States) and Age among HPV Infection in Men (HIM) Study Participants.
    Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32713.
    PubMed     Abstract available

  22. CASTLE PE, Burk RD, Massad LS, Eltoum IE, et al
    Epidemiological Evidence that Common HPV Types May Be Common Because of Their Ability to Evade Immune Surveillance: Results from the Women's Interagency HIV Study.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32693.
    PubMed     Abstract available

    September 2019
  23. SADRI NAHAND J, Moghoofei M, Salmaninejad A, Bahmanpour Z, et al
    Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review.
    Int J Cancer. 2019 Sep 30. doi: 10.1002/ijc.32688.
    PubMed     Abstract available

  24. KANO M, Kondo S, Wakisaka N, Wakae K, et al
    Expression of estrogen receptor alpha is associated with pathogenesis and prognosis of human papillomavirus-positive oropharyngeal cancer.
    Int J Cancer. 2019;145:1547-1557.
    PubMed     Abstract available

  25. REN J, Yang W, Su J, Ren X, et al
    Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region.
    Int J Cancer. 2019;145:1465-1474.
    PubMed     Abstract available

  26. STOLER MH, Baker E, Boyle S, Aslam S, et al
    Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology - retrospective insights from ATHENA.
    Int J Cancer. 2019 Sep 6. doi: 10.1002/ijc.32669.
    PubMed     Abstract available

    August 2019
  27. SILLING S, Soylemez U, Mauch C, Zigrino P, et al
    Human papillomavirus type 197 is not associated with skin tumors.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32646.

  28. ARROYO MUHR LS, Dillner J
    Reply to: Human papillomavirus type 197 is not associated with skin tumors.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32645.

  29. GANGKOFNER DS, Holzinger D, Schroeder L, Eichmuller SB, et al
    Patterns of antibody responses to non-viral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status.
    Int J Cancer. 2019 Aug 12. doi: 10.1002/ijc.32623.
    PubMed     Abstract available

  30. WEI F, Su Y, Yao X, Cui X, et al
    Sex differences in the incidence and clearance of anal human papillomavirus infection among heterosexual men and women in Liuzhou, China: An observational cohort study.
    Int J Cancer. 2019;145:807-816.
    PubMed     Abstract available

  31. AKGUL B, Kirschberg M, Storey A, Hufbauer M, et al
    Human papillomavirus type 8 oncoproteins E6 and E7 cooperate in downregulation of the cellular checkpoint kinase-1.
    Int J Cancer. 2019;145:797-806.
    PubMed     Abstract available

  32. GANLY I, Yang L, Giese RA, Hao Y, et al
    Periodontal pathogens are a risk factor of oral cavity squamous cell carcinoma, independent of tobacco and alcohol and human papillomavirus.
    Int J Cancer. 2019;145:775-784.
    PubMed     Abstract available

  33. RIGHOLT CH, Bozat-Emre S, Mahmud SM
    Effectiveness of school-based and high-risk human papillomavirus vaccination programs against cervical dysplasia in Manitoba, Canada.
    Int J Cancer. 2019;145:671-677.
    PubMed     Abstract available

    July 2019
  34. TAWE L, MacDuffie E, Narasimhamurthy M, Wang Q, et al
    Human Papillomavirus (HPV) Genotypes in Women with Invasive Cervical Cancer with and without Human Immunodeficiency Virus (HIV) Infection in Botswana.
    Int J Cancer. 2019 Jul 20. doi: 10.1002/ijc.32581.
    PubMed     Abstract available

  35. GIULIANO AR, Nedjai B, Lorincz AT, Schell MJ, et al
    Methylation Of Hpv 16 And Epb41l3 In Oral Gargles: Associations With Oropharyngeal Cancer Detection And Tumor Characteristics.
    Int J Cancer. 2019 Jul 15. doi: 10.1002/ijc.32570.
    PubMed     Abstract available

  36. REINHOLDT K, Thomsen LT, Dehlendorff C, Larsen HK, et al
    Human papillomavirus (HPV)-related anogenital premalignancies and cancer in renal transplant recipients: a Danish nationwide, registry-based cohort study.
    Int J Cancer. 2019 Jul 10. doi: 10.1002/ijc.32565.
    PubMed     Abstract available

  37. DOK R, Bamps M, Glorieux M, Zhao P, et al
    Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas.
    Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32558.
    PubMed     Abstract available

  38. DOVEY DE LA COUR C, Dehlendorff C, Aalborg GL, von Buchwald C, et al
    Use of nonaspirin non-steroidal anti-inflammatory drugs and risk of head and neck cancer: a nationwide case-control study.
    Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32544.
    PubMed     Abstract available

  39. BERTOLI HK, Rasmussen CL, Sand FL, Albieri V, et al
    Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina.
    Int J Cancer. 2019;145:78-86.
    PubMed     Abstract available

    June 2019
  40. PARKIN DM, Hammerl L, Ferlay J, Kantelhardt EJ, et al
    Cancer in Africa 2018: the role of infections.
    Int J Cancer. 2019 Jun 29. doi: 10.1002/ijc.32538.
    PubMed     Abstract available

  41. MCBRIDE E, Marlow LAV, Forster AS, Ridout D, et al
    Anxiety and distress following receipt of results from routine HPV primary testing in cervical screening: the Psychological Impact of Primary Screening (PIPS) study.
    Int J Cancer. 2019 Jun 28. doi: 10.1002/ijc.32540.
    PubMed     Abstract available

  42. COLDMAN AJ, van Niekerk D, Krajden M, Smith LW, et al
    Disease Detection at the 48 Month Exit Round of the HPV FOCAL Cervical Cancer Screening Trial in Women Per-Protocol Eligible for Routine Screening.
    Int J Cancer. 2019 Jun 27. doi: 10.1002/ijc.32524.
    PubMed     Abstract available

  43. MPUNGA T, Umulisa MC, Tenet V, Rugwizangoga B, et al
    Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status.
    Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32491.
    PubMed     Abstract available

  44. WOESTENBERG PJ, Bogaards JA, King AJ, Leussink S, et al
    Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
    Int J Cancer. 2019;144:2718-2727.
    PubMed     Abstract available

    May 2019
  45. DOGAN S, Xu B, Middha S, Vanderbilt CM, et al
    Identification of Prognostic Molecular Biomarkers in 157 HPV-positive and HPV-negative Squamous Cell Carcinomas of the Oropharynx.
    Int J Cancer. 2019 May 16. doi: 10.1002/ijc.32412.
    PubMed     Abstract available

    April 2019
  46. AMARO-FILHO SM, Gradissimo A, Usyk M, Moreira FCB, et al
    HPV73 a non-vaccine type causes cervical cancer.
    Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32315.
    PubMed     Abstract available

    March 2019
  47. BONDE J, Bottari F, Parvu V, Pedersen H, et al
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32291.
    PubMed     Abstract available

  48. LANDY R, Schiffman M, Sasieni PD, Cheung LC, et al
    Absolute risks of cervical precancer among women who fulfil exiting guidelines based on HPV and cytology cotesting.
    Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32268.
    PubMed     Abstract available

    February 2019
  49. VAN LEEUWEN RW, Ostrbenk A, Poljak M, van der Zee AGJ, et al
    DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort.
    Int J Cancer. 2019;144:746-754.
    PubMed     Abstract available

  50. GRAY P, Luostarinen T, Vanska S, Eriksson T, et al
    Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to nine years after vaccination (IV).
    Int J Cancer. 2019 Feb 5. doi: 10.1002/ijc.32189.
    PubMed     Abstract available

    January 2019
  51. FERRERA A, Valladares W, Cabrera Y, de la Luz Hernandez M, et al
    Performance of an HPV 16/18 E6 oncoprotein test for detection of cervical precancer and cancer.
    Int J Cancer. 2019 Jan 26. doi: 10.1002/ijc.32156.
    PubMed     Abstract available

  52. PAN J, Kavanagh K, Cuschieri K, Pollock KG, et al
    Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease.
    Int J Cancer. 2019 Jan 16. doi: 10.1002/ijc.32126.
    PubMed     Abstract available

  53. WU C, Nilsson K, Zheng Y, Ekenstierna C, et al
    Short half-life of HPV16 E6 and E7 mRNAs sensitizes HPV16-positive tonsillar cancer cell line HN26 to DNA-damaging drugs.
    Int J Cancer. 2019;144:297-310.
    PubMed     Abstract available

  54. AL-SAHAF S, Hunter KD, Bolt R, Ottewell PD, et al
    The IL-1/IL-1R axis induces greater fibroblast-derived chemokine release in human papillomavirus-negative compared to positive oropharyngeal cancer.
    Int J Cancer. 2019;144:334-344.
    PubMed     Abstract available

  55. LEEMAN A, Del Pino M, Marimon L, Torne A, et al
    Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology-screened referral population.
    Int J Cancer. 2019;144:160-168.
    PubMed     Abstract available

    December 2018
  56. GRABER JM, Harris G, Black K, Lucchini RG, et al
    Excess HPV-related head and neck cancer in the World Trade Center Health Program General Responder cohort.
    Int J Cancer. 2018 Dec 17. doi: 10.1002/ijc.32070.
    PubMed     Abstract available

  57. ANDREASSEN T, Hansen BT, Engesaeter B, Hashim D, et al
    Psychological Effect of Cervical Cancer Screening When Changing Primary Screening Method From Cytology to hrHPV testing.
    Int J Cancer. 2018 Dec 14. doi: 10.1002/ijc.32067.
    PubMed     Abstract available

  58. SULTANA F, Winch K, Saville M, Brotherton JM, et al
    Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination?
    Int J Cancer. 2018 Dec 10. doi: 10.1002/ijc.32050.
    PubMed     Abstract available

  59. RADER JS, Tsaih SW, Fullin D, Murray MW, et al
    Genetic variations in human papillomavirus and cervical cancer outcomes.
    Int J Cancer. 2018 Dec 4. doi: 10.1002/ijc.32038.
    PubMed     Abstract available

  60. HALEC G, Scott ME, Farhat S, Darragh TM, et al
    Toll-like receptors: Important immune checkpoints in the regression of cervical intra-epithelial neoplasia 2.
    Int J Cancer. 2018;143:2884-2891.
    PubMed     Abstract available

    November 2018
  61. UTADA M, Chernyavskiy P, Lee WJ, Franceschi S, et al
    Increasing risk of uterine cervical cancer among young Japanese women: Comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32014.
    PubMed     Abstract available

  62. POLMAN NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, et al
    Management of HPV-Positive Women in Cervical Screening Using Results from Two Consecutive Screening Rounds.
    Int J Cancer. 2018 Nov 22. doi: 10.1002/ijc.32004.
    PubMed     Abstract available

  63. REN S, Gaykalova D, Wang J, Guo T, et al
    Discovery and development of differentially methylated regions in human papillomavirus-related oropharyngeal squamous cell carcinoma.
    Int J Cancer. 2018;143:2425-2436.
    PubMed     Abstract available

  64. RATAJ O, Haedicke-Jarboui J, Stubenrauch F, Iftner T, et al
    Brd4 inhibition suppresses HPV16 E6 expression and enhances chemoresponse: A potential new target in cervical cancer therapy.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31986.
    PubMed     Abstract available

  65. COOK DA, Krajden M, Brentnall AR, Gondara L, et al
    Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31976.
    PubMed     Abstract available

  66. SAHNANE N, Ottini G, Turri-Zanoni M, Furlan D, et al
    Comprehensive analysis of HPV infection, EGFR exon 20 mutations and LINE1 hypomethylation as risk factors for malignant transformation of sinonasal inverted papilloma to squamous cell carcinoma.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31971.
    PubMed     Abstract available

  67. ISIDEAN SD, Wang Y, Mayrand MH, Ratnam S, et al
    Assessing the Time Dependence of Prognostic Values of Cytology and Human Papillomavirus Testing in Cervical Cancer Screening.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31970.
    PubMed     Abstract available

  68. PIMENOFF VN, Tous S, Benavente Y, Alemany L, et al
    Distinct geographic clustering of oncogenic human papillomaviruses multiple infections in cervical cancers: results from a worldwide cross-sectional study.
    Int J Cancer. 2018 Nov 2. doi: 10.1002/ijc.31964.
    PubMed     Abstract available

  69. LEHTINEN M, Luostarinen T, Vanska S, Soderlund-Strand A, et al
    Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III).
    Int J Cancer. 2018;143:2299-2310.
    PubMed     Abstract available

    October 2018
  70. HUEBBERS CU, Verhees F, Poluschkin L, Olthof NC, et al
    Upregulation of AKR1C1 and AKR1C3 expression in OPSCC with integrated HPV16 and HPV-negative tumors is an indicator of poor prognosis.
    Int J Cancer. 2018 Oct 27. doi: 10.1002/ijc.31954.

  71. KAMINENI A, Tiro JA, Beaber EF, Silverberg MJ, et al
    Cervical Cancer Screening Research in the PROSPR I Consortium: Rationale, Methods, and Baseline Findings from a U.S. Cohort.
    Int J Cancer. 2018 Oct 24. doi: 10.1002/ijc.31940.
    PubMed     Abstract available

    September 2018
  72. SAND FL, Munk C, Frederiksen K, Junge J, et al
    Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
    Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31883.
    PubMed     Abstract available

  73. WANG Q, Song R, Zhao C, Liu H, et al
    HPV16 E6 promotes cervical cancer cell migration and invasion by downregulation of NHERF1.
    Int J Cancer. 2018 Sep 19. doi: 10.1002/ijc.31876.
    PubMed     Abstract available

  74. HUFBAUER M, Maltseva M, Meinrath J, Lechner A, et al
    HPV16 increases the number of migratory cancer stem cells and modulates their miRNA expression profile in oropharyngeal cancer.
    Int J Cancer. 2018;143:1426-1439.
    PubMed     Abstract available

  75. TAO Y, Sturgis EM, Huang Z, Sun Y, et al
    A TGF-beta1 genetic variant at the miRNA187 binding site significantly modifies risk of HPV16-associated oropharyngeal cancer.
    Int J Cancer. 2018;143:1327-1334.
    PubMed     Abstract available

  76. SNOEK BC, Verlaat W, Babion I, Novianti PW, et al
    Genome-wide microRNA analysis of HPV-positive self-samples yields novel triage markers for early detection of cervical cancer.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31855.
    PubMed     Abstract available

  77. BAUSSANO I, Lazzarato F, Ronco G, Franceschi S, et al
    Impacts of human papillomavirus vaccination for different populations: A modeling study.
    Int J Cancer. 2018;143:1086-1092.
    PubMed     Abstract available

    August 2018
  78. JOSHI S, Muwonge R, Kulkarni V, Deodhar K, et al
    Incidence of cervical intraepithelial neoplasia in women infected with human immunodeficiency virus (HIV) with no evidence of disease at baseline: results of a prospective cohort study with up to 6.4 years of follow-up from India.
    Int J Cancer. 2018 Aug 22. doi: 10.1002/ijc.31826.
    PubMed     Abstract available

  79. CAMPOS NG, Tsu V, Jeronimo J, Regan C, et al
    Health impact of delayed implementation of cervical cancer screening programs in India: A modelling analysis.
    Int J Cancer. 2018 Aug 21. doi: 10.1002/ijc.31823.
    PubMed     Abstract available

  80. FORSLUND O, Miriam Elfstrom K, Lamin H, Dillner J, et al
    Int J Cancer. 2018 Aug 19. doi: 10.1002/ijc.31819.
    PubMed     Abstract available

  81. GOMIH A, Smith JS, North KE, Hudgens MG, et al
    DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions.
    Int J Cancer. 2018;143:552-560.
    PubMed     Abstract available

  82. HUANG X, Li C, Li F, Zhao J, et al
    Cervicovaginal microbiota composition correlates with the acquisition of high-risk human papillomavirus types.
    Int J Cancer. 2018;143:621-634.
    PubMed     Abstract available

    July 2018
  83. JIT M, Brisson M
    Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus.
    Int J Cancer. 2018;143:317-323.
    PubMed     Abstract available

  84. MEZA R, Lau YK, Thomas TB, Carey TE, et al
    DNA Concentration from self samples for HPV testing.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31666.

    June 2018
  85. GUSTAVSSON I, Aarnio R, Berggrund M, Hedlund-Lindberg J, et al
    Randomized study of HPV prevalence and detection of CIN2+ in vaginal self-sampling compared to cervical specimens collected by medical personnel.
    Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31637.
    PubMed     Abstract available

  86. REZHAKE R, Hu SY, Zhao S, Xu XQ, et al
    Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
    Int J Cancer. 2018 Jun 26. doi: 10.1002/ijc.31633.
    PubMed     Abstract available

    April 2018
  87. THAMSBORG LH, Napolitano G, Larsen LG, Lynge E, et al
    Impact of HPV-vaccination on outcome of cervical cytology screening in Denmark - a register based cohort study.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31568.
    PubMed     Abstract available

  88. DE STROOPER LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, et al
    Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31539.
    PubMed     Abstract available

  89. HANSEN BT, Orumaa M, Lie AK, Brennhovd B, et al
    Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956-2015.
    Int J Cancer. 2018;142:1586-1593.
    PubMed     Abstract available

  90. SCHROEDER L, Wichmann G, Willner M, Michel A, et al
    Antibodies against human papillomaviruses as diagnostic and prognostic biomarker in patients with neck squamous cell carcinoma from unknown primary tumor.
    Int J Cancer. 2018;142:1361-1368.
    PubMed     Abstract available

  91. BEYNON RA, Lang S, Schimansky S, Penfold CM, et al
    Tobacco smoking and alcohol drinking at diagnosis of head and neck cancer and all-cause mortality: Results from Head and Neck 5000, a prospective observational cohort of people with head and neck cancer.
    Int J Cancer. 2018 Apr 1. doi: 10.1002/ijc.31416.

    March 2018
  92. ANNUNZIATA C, Pezzuto F, Greggi S, Ionna F, et al
    Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.
    Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31412.
    PubMed     Abstract available

  93. VINTERMYR OK, Andersland MS, Bjorge T, Skar R, et al
    Human papillomavirus type specific risk of progression and remission during long term follow-up of equivocal and low grade HPV-positive cervical smears.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31390.
    PubMed     Abstract available

  94. KELLEN E, Benoy I, Vanden Broeck D, Martens P, et al
    A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31391.
    PubMed     Abstract available

  95. WEI F, Li M, Wu X, Yin K, et al
    The prevalence and concordance of human papillomavirus infection in different anogenital sites among men and women in Liuzhou, China: A population-based study.
    Int J Cancer. 2018;142:1244-1251.
    PubMed     Abstract available

  96. YU L, Jiang M, Qu P, Wu Z, et al
    Clinical Evaluation of Human Papillomavirus 16/18 Oncoprotein Test for Cervical Cancer Screening and HPV Positive Women Triage.
    Int J Cancer. 2018 Mar 9. doi: 10.1002/ijc.31368.
    PubMed     Abstract available

  97. LEHTINEN M, Soderlund-Strand A, Vanska S, Luostarinen T, et al
    Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
    Int J Cancer. 2018;142:949-958.
    PubMed     Abstract available

    February 2018
  98. DEL MISTRO A, Adcock R, Carozzi F, Gillio-Tos A, et al
    HPV genotyping for the cross-sectional and longitudinal probability of developing CIN2.
    Int J Cancer. 2018 Feb 17. doi: 10.1002/ijc.31326.
    PubMed     Abstract available

  99. RIETBERGEN MM, van Bokhoven AAJD, Lissenberg-Witte BI, Heideman DAM, et al
    Epidemiologic associations of HPV-positive oropharyngeal cancer and (pre)cancerous cervical lesions.
    Int J Cancer. 2018 Feb 14. doi: 10.1002/ijc.31315.
    PubMed     Abstract available

    January 2018
  100. GRAY P, Palmroth J, Luostarinen T, Apter D, et al
    Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females - Post-hoc analysis of a community-randomized clinical trial (II).
    Int J Cancer. 2018 Jan 29. doi: 10.1002/ijc.31281.
    PubMed     Abstract available

  101. LEEMAN JE, McBride SM, Spielsinger D, Sherman EJ, et al
    Head and Neck Cancers Associated with Exposure to the September 11, 2001 World Trade Center Terrorist Attacks.
    Int J Cancer. 2018 Jan 25. doi: 10.1002/ijc.31277.
    PubMed     Abstract available

  102. DE KOK IMCM, Korfage IJ, van den Hout WB, Helmerhorst TJM, et al
    Quality of life assumptions determine which cervical cancer screening strategies are cost-effective.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31265.
    PubMed     Abstract available

  103. CUSCHIERI K, Ronco G, Lorincz A, Smith L, et al
    Eurogin Roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programmes.
    Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31261.
    PubMed     Abstract available

  104. STEINBACH A, Riemer AB
    Immune evasion mechanisms of human papillomavirus: An update.
    Int J Cancer. 2018;142:224-229.
    PubMed     Abstract available

  105. MERMOD M, Hiou-Feige A, Bovay E, Roh V, et al
    Mouse model of post-surgical primary tumor recurrence and regional lymph node metastasis progression in HPV-related head and neck cancer.
    Int J Cancer. 2018 Jan 4. doi: 10.1002/ijc.31240.
    PubMed     Abstract available

    December 2017
  106. LUOSTARINEN T, Apter D, Dillner J, Eriksson T, et al
    Vaccination protects against invasive HPV-associated cancers.
    Int J Cancer. 2017 Dec 26. doi: 10.1002/ijc.31231.

  107. ARROYO MUHR LS, Bzhalava Z, Hortlund M, Lagheden C, et al
    Viruses in cancers among the immunosuppressed.
    Int J Cancer. 2017;141:2498-2504.
    PubMed     Abstract available

  108. GULTEKIN M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, et al
    Initial results of population based cervical cancer screening program using hpv testing in one million turkish women.
    Int J Cancer. 2017 Dec 13. doi: 10.1002/ijc.31212.
    PubMed     Abstract available

  109. STANGL S, Tontcheva N, Sievert W, Shevtsov M, et al
    Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology
    Int J Cancer. 2017 Dec 13. doi: 10.1002/ijc.31213.
    PubMed     Abstract available

  110. SAND FL, Frederiksen K, Munk C, Jensen SM, et al
    Long-Term Risk of Cervical Cancer Following Conization of Cervical Intraepithelial Neoplasia Grade 3 - A Danish Nationwide Cohort Study.
    Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31202.
    PubMed     Abstract available

  111. KANG YJ, Smith M, Barlow E, Coffey K, et al
    Vulvar cancer in high-income countries: Increasing burden of disease.
    Int J Cancer. 2017;141:2174-2186.
    PubMed     Abstract available

    November 2017
  112. RAJENDRA S, Yang T, Xuan W, Sharma P, et al
    Active human papillomavirus involvement in Barrett's dysplasia and oesophageal adenocarcinoma is characterized by wild-type p53 and aberrations of the retinoblastoma protein pathway.
    Int J Cancer. 2017;141:2037-2049.
    PubMed     Abstract available

  113. RASMUSSEN CL, Sand FL, Hoffmann Frederiksen M, Andersen KK, et al
    Does HPV status influence survival after vulvar cancer?
    Int J Cancer. 2017 Nov 1. doi: 10.1002/ijc.31139.
    PubMed     Abstract available

    October 2017
  114. LANDY R, Windridge P, Gillman MS, Sasieni PD, et al
    What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31094.
    PubMed     Abstract available

  115. ZHU L, Sturgis EM, Zhang H, Lu Z, et al
    Genetic variants in microRNA-binding sites of DNA repair genes as predictors of recurrence in patients with squamous cell carcinoma of the oropharynx.
    Int J Cancer. 2017;141:1355-1364.
    PubMed     Abstract available

    September 2017
  116. FABER MT, Sand FL, Albieri V, Norrild B, et al
    Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva.
    Int J Cancer. 2017;141:1161-1169.
    PubMed     Abstract available

  117. ZHANG Q, Dong L, Hu S, Feng R, et al
    Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China.
    Int J Cancer. 2017;141:1110-1119.
    PubMed     Abstract available

    August 2017
  118. RAKISLOVA N, Clavero O, Alemany L, Saco A, et al
    "Histological characteristics of HPV-associated and -independent squamous cell carcinomas of the vulva: A study of 1594 cases".
    Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.31006.
    PubMed     Abstract available

  119. VASILJEVIC N, Carter PD, Reuter C, Warman R, et al
    Role of quantitative p16INK4A mRNA assay and digital reading of p16INK4A immunostained sections in diagnosis of cervical intraepithelial neoplasia.
    Int J Cancer. 2017;141:829-836.
    PubMed     Abstract available

  120. CLARKE MA, Luhn P, Gage JC, Bodelon C, et al
    Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer.
    Int J Cancer. 2017;141:701-710.
    PubMed     Abstract available

  121. VELENTZIS LS, Caruana M, Simms KT, Lew JB, et al
    How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccina
    Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30926.
    PubMed     Abstract available

    July 2017
  122. KHAN S, Oosterhuis K, Wunderlich K, Bunnik EM, et al
    Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.
    Int J Cancer. 2017;141:393-404.
    PubMed     Abstract available

  123. BROTHERTON JM, Tabrizi SN, Phillips S, Pyman J, et al
    Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30871.
    PubMed     Abstract available

  124. VELDHUIJZEN NJ, Polman NJ, Snijders PJF, Meijer CJLM, et al
    Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30865.
    PubMed     Abstract available

  125. CABEL L, Bidard FC, Servois V, Cacheux W, et al
    HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30863.
    PubMed     Abstract available

    June 2017
  126. MATSUMOTO K, Yaegashi N, Iwata T, Yamamoto K, et al
    Early impact of the Japanese immunization program implemented before the HPV vaccination crisis.
    Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30855.

  127. HOLZINGER D, Wichmann G, Baboci L, Michel A, et al
    Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma.
    Int J Cancer. 2017;140:2748-2757.
    PubMed     Abstract available

  128. BOSCOLO-RIZZO P, Dietz A
    The AJCC/UICC eighth edition for staging head and neck cancers: Is it wise to de-escalate treatment regimens in p16-positive oropharyngeal cancer patients?
    Int J Cancer. 2017 Jun 14. doi: 10.1002/ijc.30837.

    May 2017
  129. LAM JU, Rebolj M, Moller Ejegod D, Pedersen H, et al
    Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms.
    Int J Cancer. 2017;140:2212-2219.
    PubMed     Abstract available

  130. LOPES RDVC, Teixeira JA, Marchioni D, Villa LL, et al
    Dietary intake of selected nutrients and persistence of HPV infection in men.
    Int J Cancer. 2017 May 9. doi: 10.1002/ijc.30772.
    PubMed     Abstract available

  131. BALERMPAS P, Rodel F, Krause M, Linge A, et al
    The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Int J Cancer. 2017 May 8. doi: 10.1002/ijc.30770.
    PubMed     Abstract available

  132. AGORASTOS T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, et al
    Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30761.

  133. SHEN C, Liu Y, Shi S, Zhang R, et al
    Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region up-regulating the allele-specific MYC expression in HeLa cells.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30763.
    PubMed     Abstract available

  134. NICOLAS-PARRAGA S, Alemany L, de Sanjose S, Bosch FX, et al
    Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma.
    Int J Cancer. 2017;140:2092-2100.
    PubMed     Abstract available

    April 2017
  135. RYSER M, Guignard A, Taylor S
    Letter to the Editor in response to Herweijer E., Sundstrom K., Ploner A., Uhnoo I., Sparen P. and Arnheim-Dahlstrom L. (2016), Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
    Int J Cancer. 2017 Apr 29. doi: 10.1002/ijc.30753.

  136. FU XI L, Schiffman M, Ke Y, Hughes JP, et al
    Type-dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18.
    Int J Cancer. 2017;140:1747-1756.
    PubMed     Abstract available

  137. DE MARTEL C, Plummer M, Vignat J, Franceschi S, et al
    Worldwide burden of cancer attributable to HPV by site, country and HPV type.
    Int J Cancer. 2017 Apr 1. doi: 10.1002/ijc.30716.
    PubMed     Abstract available

    March 2017
  138. GHEIT T, Anantharaman D, Holzinger D, Alemany L, et al
    Role of mucosal high-risk human papillomavirus types in head and neck cancers in central India.
    Int J Cancer. 2017 Mar 29. doi: 10.1002/ijc.30712.
    PubMed     Abstract available

  139. CHEOL PARK G, Roh JL, Cho KJ, Seung Kim J, et al
    18 F-FDG PET/CT vs. human papillomavirus, p16 and Epstein-Barr virus detection in cervical metastatic lymph nodes for identifying primary tumors.
    Int J Cancer. 2017;140:1405-1412.
    PubMed     Abstract available

  140. MEZEI AK, Armstrong HL, Pedersen HN, Campos NG, et al
    Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review.
    Int J Cancer. 2017 Mar 15. doi: 10.1002/ijc.30695.
    PubMed     Abstract available

  141. DAS GHOSH D, Mukhopadhyay I, Bhattacharya A, Roy Chowdhury R, et al
    Impact of genetic variations and transcriptional alterations of HLA class I genes on cervical cancer pathogenesis.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30681.
    PubMed     Abstract available

  142. PRIGGE ES, Arbyn M, von Knebel Doeberitz M, Reuschenbach M, et al
    Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis.
    Int J Cancer. 2017;140:1186-1198.
    PubMed     Abstract available

  143. SCHNELLE C, Whiteman DC, Porceddu SV, Panizza BJ, et al
    Past sexual behaviors and risks of oropharyngeal squamous cell carcinoma: a case-case comparison.
    Int J Cancer. 2017;140:1027-1034.
    PubMed     Abstract available

    February 2017
  144. JEHANNIN-LIGIER K, Belot A, Guizard AV, Bossard N, et al
    Incidence Trends for Potentially Human Papilloma Virus-Related and -Unrelated Head and Neck Cancers in France using Population-based Cancer Registries Data: 1980-2012.
    Int J Cancer. 2017 Feb 6. doi: 10.1002/ijc.30631.
    PubMed     Abstract available

  145. LIEDERBACH E, Kyrillos A, Wang CH, Liu JC, et al
    The national landscape of human papillomavirus-associated oropharynx squamous cell carcinoma.
    Int J Cancer. 2017;140:504-512.
    PubMed     Abstract available

    January 2017
  146. HOFFMAN SR, Le T, Lockhart A, Sanusi A, et al
    Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review.
    Int J Cancer. 2017 Jan 25. doi: 10.1002/ijc.30623.

  147. RODRIGUEZ AC, Avila C, Herrero R, Hildesheim A, et al
    Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-year follow-up of the Guanacaste cohort.
    Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30614.
    PubMed     Abstract available

  148. MITTAL S, Basu P, Muwonge R, Banerjee D, et al
    Risk of high grade precancerous lesions and invasive cancers in high risk HPV positive women with normal cervix or CIN 1 at baseline - a population based cohort study.
    Int J Cancer. 2017 Jan 20. doi: 10.1002/ijc.30609.
    PubMed     Abstract available

  149. ANANTHARAMAN D, Abedi-Ardekani B, Beachler DC, Gheit T, et al
    Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer.
    Int J Cancer. 2017 Jan 20. doi: 10.1002/ijc.30608.
    PubMed     Abstract available

  150. POLMAN NJ, Uijterwaal MH, Witte BI, Berkhof J, et al
    Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.
    Int J Cancer. 2017;140:423-430.
    PubMed     Abstract available

    December 2016
  151. WENTZENSEN N, Arbyn M, Berkhof J, Bower M, et al
    Eurogin 2016 Roadmap: How HPV knowledge is changing screening practice.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30579.
    PubMed     Abstract available

  152. HATANO T, Sano D, Takahashi H, Hyakusoku H, et al
    Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPV-associated head and neck squamous cell carcinoma cell lines.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30589.
    PubMed     Abstract available

  153. BOGANI G, Chiappa V, Martinelli F, Raspagliesi F, et al
    Type-Specific HPV Infection Correlates with Risk of Recurrence of Vulvar Intraepithelial Neoplasia Usual Type.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30585.

  154. CHEN W, Molijn A, Enqi W, Zhang X, et al
    The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China.
    Int J Cancer. 2016;139:2687-2697.
    PubMed     Abstract available

  155. CAMPOS NG, Tsu V, Jeronimo J, Mvundura M, et al
    To Expand Coverage, or Increase Frequency: Quantifying the Tradeoffs between Equity and Efficiency Facing Cervical Cancer Screening Programs in Low-Resource Settings.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30551.
    PubMed     Abstract available

    November 2016
  156. KOCSIS A, Takacs T, Jeney C, Schaff Z, et al
    Performance of a New HPV and Biomarker Assay in Management of hrHPV Positive Women: Subanalysis of the Ongoing Multicenter TRACE Clinical Trial (n>6,000) to Evaluate POU4F3 as a Potential Biomarker of Cervical Precancer and Cancer.
    Int J Cancer. 2016 Nov 22. doi: 10.1002/ijc.30534.
    PubMed     Abstract available

  157. WAKEHAM K, Kavanagh K, Cuschieri K, Millan D, et al
    HPV status and favorable outcome in vulvar squamous cancer.
    Int J Cancer. 2016 Nov 16. doi: 10.1002/ijc.30523.
    PubMed     Abstract available

  158. FU TC, Carter JJ, Hughes JP, Feng Q, et al
    Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women.
    Int J Cancer. 2016;139:2201-12.
    PubMed     Abstract available

  159. TAINIO K, Jakobsson M, Louvanto K, Kalliala I, et al
    Randomised trial on treatment of vaginal intraepithelial neoplasia-Imiquimod, laser vaporisation and expectant management.
    Int J Cancer. 2016;139:2353-8.
    PubMed     Abstract available

    October 2016
  160. HOLT HK, Zhang L, Zhao FH, Hu SY, et al
    Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.
    Int J Cancer. 2016 Oct 11. doi: 10.1002/ijc.30468.
    PubMed     Abstract available

  161. SCHIFFMAN M, Yu K, Zuna R, Terence Dunn S, et al
    Proof-of-principle study of a novel cervical screening and triage strategy: computer-analyzed cytology to decide which HPV-positive women are likely to have >/=CIN2.
    Int J Cancer. 2016 Oct 1. doi: 10.1002/ijc.30456.
    PubMed     Abstract available

    September 2016
  162. OGILVIE GS, Krajden M, van Niekerk D, Smith LW, et al
    HPV For Cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid based cytology for cervical cancer.
    Int J Cancer. 2016 Sep 29. doi: 10.1002/ijc.30454.
    PubMed     Abstract available

  163. SUDENGA SL, Nelson Torres B, Fulp WJ, Silva R, et al
    Country-Specific HPV-related Genital Disease Among Men Residing in Brazil, Mexico, and the United States: The HIM Study.
    Int J Cancer. 2016 Sep 28. doi: 10.1002/ijc.30452.
    PubMed     Abstract available

  164. XI LF, Schiffman M, Koutsky LA, Hughes JP, et al
    Variant-specific persistence of infections with human papillomavirus Types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial neoplasia.
    Int J Cancer. 2016;139:1098-105.
    PubMed     Abstract available

    August 2016
  165. ISIDEAN SD, Mayrand MH, Ramanakumar AV, Gilbert L, et al
    Human Papillomavirus Testing versus Cytology in Primary Cervical Cancer Screening: End-of-Study and Extended Follow-Up Results from the Canadian Cervical Cancer Screening Trial (CCCaST).
    Int J Cancer. 2016 Aug 18. doi: 10.1002/ijc.30385.
    PubMed     Abstract available

  166. ZOU H, Tabrizi SN, Grulich AE, Hocking JS, et al
    Antibody responses following incident anal and penile infection with human papillomavirus in teenage men who have sex with men.
    Int J Cancer. 2016;139:639-46.
    PubMed     Abstract available

    July 2016
  167. GUO T, Gaykalova DA, Considine M, Wheelan S, et al
    Characterization of functionally active gene fusions in human papillomavirus related oropharyngeal squamous cell carcinoma.
    Int J Cancer. 2016;139:373-82.
    PubMed     Abstract available

    May 2016
  168. CARLANDER C, Wagner P, Svedhem V, Elfgren K, et al
    Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden.
    Int J Cancer. 2016 May 13. doi: 10.1002/ijc.30188.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Sexually Transmitted Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.